The American Lung Association has partnered with Sanofi to educate Americans about the flu and steps they can take to protect themselves from severe flu illness, with the goal of increasing vaccination rates.
Altered B cell function in children with mitochondrial disorders led to a weaker and less diverse antibody response to viral infections, according to NIH researchers.
A phase 1 clinical trial will test an experimental mRNA universal influenza vaccine known as H1ssF-3928 mRNA-LNP.
The method, based on triplex-forming probe technology, opens up new options for detecting viruses like SARS-CoV-2, influenza A, or RSV.
Read More
Seizure risks, a needle-free vaccine patch, and a compound that may limit flu replication—here are five flu stories you should check out this week.
Read More
The US FDA issued an emergency use authorization for the Lucira COVID-19 & Flu Test, the first over-the-counter (OTC) at-home diagnostic test that can differentiate and detect influenza A and B and SARS-CoV-2.
Read More
Researchers say the discovery is essential to developing future therapies to limit viral infection and improve the health of patients with chronic lung disease.
Read More
The preclinical research demonstrated the ability of Infectimune to significantly boost CD4 T cell activity, suggesting that Infectimune-based vaccines could provide durable protection against seasonal flu and potentially emerging pandemic flu.
Read More
The trial will assess the safety, tolerability, and immunogenicity of the IIV4 candidate in approximately 150 healthy participants, aged 18 to 50.
Read More
The 40-month project may culminate in a prototype bivalent vaccine candidate that is effective against both the H5N1 and H7N9 strains of influenza, according to Access to Advanced Health Institute.
Read More
Researchers have discovered a compound that inhibits the body’s own methyltransferase MTr1, which limits the replication of influenza viruses and may lead to the development of new treatments for the flu.
Read More
A poll of 1,234 adults aimed to determine how many households had recently been impacted by RSV, COVID-19 or the flu and to gauge their concern about whether they’re worried about becoming ill with one of the viruses.
Read More
BD received FDA emergency use authorization for its new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and respiratory syncytial virus (RSV).
Read More
A survey found individuals with COPD were overwhelmingly positive about the prospect of taking an antiviral nasal spray throughout the winter season to prevent COPD flare-ups.
Read More
With the COVID, flu and RSV tripledemic, new research spotlights the effects of COVID-19 variants and multiple viruses on young patients.
Read More